Palvella Therapeutics, Inc.
PVLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $693,620 | $249,129 | $62,306 | $26,711 |
| - Cash | $63,567 | $70,433 | $75,626 | $83,602 |
| + Debt | $0 | $14,511 | $0 | $0 |
| Enterprise Value | $630,053 | $193,207 | -$13,320 | -$56,891 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $342 | -$8,117 | -$6,970 | -$4,366 |
| % Margin | – | – | – | – |
| Net Income | -$11,345 | -$9,471 | -$8,185 | -$3,951 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.03 | -0.86 | -3.68 | -0.88 |
| % Growth | -19.8% | 76.6% | -318.2% | – |
| Operating Cash Flow | $0 | -$5,434 | -$6,768 | -$5,393 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$5,434 | -$6,768 | -$5,393 |